The MMAA Knockout Raji Polyclonal Cells are a CRISPR/Cas9-mediated gene disruption polyclonal knockout population derived from the Raji B-lymphocyte line, targeting the MMAA locus to create a loss-of-function model for mitochondrial adenosylcobalamin (AdoCbl) synthesis and methylmalonic acid metabolism. The heterogeneous polyclonal format avoids clonal bias and is ideal for functional pathway analysis.
Raji cells, an EBV-positive Burkitt??s lymphoma-derived B-lymphoblastoid suspension line, serve as a well-characterized model for B-cell lymphoma biology, EBV latency, and immune signaling. Their robust mitochondrial metabolism and ease of culture make them suitable for studying metabolic gene disruptions in a malignant B-cell context.
MMAA protein is a mitochondrial chaperone critical for AdoCbl production, the coenzyme for methylmalonyl-CoA mutase (MUT). It interacts with MMAB and MMACHC to process cobalamin and deliver it to MUT. Loss of MMAA halts AdoCbl synthesis, preventing MUT from converting methylmalonyl-CoA to succinyl-CoA, a key step in propionate metabolism and TCA cycle replenishment. Consequently, methylmalonic acid accumulates, recapitulating methylmalonic aciduria. MMAA activity is influenced by mitochondrial biogenesis regulators and oxidative stress sensors, and its disruption diminishes succinyl-CoA and TCA cycle intermediates, underscoring its role in mitochondrial cofactor biogenesis and metabolic homeostasis.
In the Raji B-cell lymphoma environment, MMAA knockout couples a well-defined metabolic defect with a malignant background, enabling investigation of metabolic fragility in lymphoma cells. Impaired AdoCbl synthesis may heighten reliance on alternative carbon sources and sensitize cells to mitochondrial stress, offering insights into B-cell metabolic adaptations and potential therapeutic targets in methylmalonic aciduria-related encephalopathy and related disorders.
Applications include modeling methylmalonic aciduria, vitamin B12 metabolism studies, and mitochondrial dysfunction research. Assays such as methylmalonic acid quantification by LC-MS, immunoblotting for MMAA, RT-qPCR validation, cobalamin coenzyme activity tests, mitochondrial respiration measurements, and viability under metabolic stress are readily performed. The polyclonal population is also amenable to high-throughput drug screening for agents that restore MUT activity or bypass the metabolic block. For further information, please contact Ascent Research.
